RT @APassaroMD: 🆕@CD_AACR Functional STK11 mutations is associated with resistance to ICIs in #lungcancer & is reversed by STAT3 knockdown…
RT @APassaroMD: 🆕@CD_AACR Functional STK11 mutations is associated with resistance to ICIs in #lungcancer & is reversed by STAT3 knockdown…
RT @APassaroMD: 🆕@CD_AACR Functional STK11 mutations is associated with resistance to ICIs in #lungcancer & is reversed by STAT3 knockdown…
RT @APassaroMD: 🆕@CD_AACR Functional STK11 mutations is associated with resistance to ICIs in #lungcancer & is reversed by STAT3 knockdown…
RT @APassaroMD: 🆕@CD_AACR Functional STK11 mutations is associated with resistance to ICIs in #lungcancer & is reversed by STAT3 knockdown…
Resistance to Durva and Durva+Treme is associated with functional STK11 mutations in NSCLC and reversed by STAT3 knockdown: https://t.co/fnpNUfYIHH STAT3 inhibitors have struggled clinic so maybe a role for protein degradation here?
RT @APassaroMD: 🆕@CD_AACR Functional STK11 mutations is associated with resistance to ICIs in #lungcancer & is reversed by STAT3 knockdown…
RT @APassaroMD: 🆕@CD_AACR Functional STK11 mutations is associated with resistance to ICIs in #lungcancer & is reversed by STAT3 knockdown…
RT @APassaroMD: 🆕@CD_AACR Functional STK11 mutations is associated with resistance to ICIs in #lungcancer & is reversed by STAT3 knockdown…
RT @APassaroMD: 🆕@CD_AACR Functional STK11 mutations is associated with resistance to ICIs in #lungcancer & is reversed by STAT3 knockdown…
RT @APassaroMD: 🆕@CD_AACR Functional STK11 mutations is associated with resistance to ICIs in #lungcancer & is reversed by STAT3 knockdown…
Nice work from AstraZeneca exploring ICI resistance mechanism based on clinical trial data. However, I hope we can stop using CT26 ( a colon cancer cell line from BALB/c mouse) to study lung cancer in the subcutaneous injection setting...I guess this is fr
RT @APassaroMD: 🆕@CD_AACR Functional STK11 mutations is associated with resistance to ICIs in #lungcancer & is reversed by STAT3 knockdown…
RT @APassaroMD: 🆕@CD_AACR Functional STK11 mutations is associated with resistance to ICIs in #lungcancer & is reversed by STAT3 knockdown…
RT @APassaroMD: 🆕@CD_AACR Functional STK11 mutations is associated with resistance to ICIs in #lungcancer & is reversed by STAT3 knockdown…
RT @APassaroMD: 🆕@CD_AACR Functional STK11 mutations is associated with resistance to ICIs in #lungcancer & is reversed by STAT3 knockdown…
RT @APassaroMD: 🆕@CD_AACR Functional STK11 mutations is associated with resistance to ICIs in #lungcancer & is reversed by STAT3 knockdown…
RT @APassaroMD: 🆕@CD_AACR Functional STK11 mutations is associated with resistance to ICIs in #lungcancer & is reversed by STAT3 knockdown…
RT @APassaroMD: 🆕@CD_AACR Functional STK11 mutations is associated with resistance to ICIs in #lungcancer & is reversed by STAT3 knockdown…
RT @APassaroMD: 🆕@CD_AACR Functional STK11 mutations is associated with resistance to ICIs in #lungcancer & is reversed by STAT3 knockdown…
RT @APassaroMD: 🆕@CD_AACR Functional STK11 mutations is associated with resistance to ICIs in #lungcancer & is reversed by STAT3 knockdown…
RT @APassaroMD: 🆕@CD_AACR Functional STK11 mutations is associated with resistance to ICIs in #lungcancer & is reversed by STAT3 knockdown…
RT @APassaroMD: 🆕@CD_AACR Functional STK11 mutations is associated with resistance to ICIs in #lungcancer & is reversed by STAT3 knockdown…
RT @APassaroMD: 🆕@CD_AACR Functional STK11 mutations is associated with resistance to ICIs in #lungcancer & is reversed by STAT3 knockdown…
RT @APassaroMD: 🆕@CD_AACR Functional STK11 mutations is associated with resistance to ICIs in #lungcancer & is reversed by STAT3 knockdown…
RT @APassaroMD: 🆕@CD_AACR Functional STK11 mutations is associated with resistance to ICIs in #lungcancer & is reversed by STAT3 knockdown…
RT @APassaroMD: 🆕@CD_AACR Functional STK11 mutations is associated with resistance to ICIs in #lungcancer & is reversed by STAT3 knockdown…
RT @APassaroMD: 🆕@CD_AACR Functional STK11 mutations is associated with resistance to ICIs in #lungcancer & is reversed by STAT3 knockdown…
RT @APassaroMD: 🆕@CD_AACR Functional STK11 mutations is associated with resistance to ICIs in #lungcancer & is reversed by STAT3 knockdown…
RT @APassaroMD: 🆕@CD_AACR Functional STK11 mutations is associated with resistance to ICIs in #lungcancer & is reversed by STAT3 knockdown…
RT @APassaroMD: 🆕@CD_AACR Functional STK11 mutations is associated with resistance to ICIs in #lungcancer & is reversed by STAT3 knockdown…
RT @APassaroMD: 🆕@CD_AACR Functional STK11 mutations is associated with resistance to ICIs in #lungcancer & is reversed by STAT3 knockdown…
RT @APassaroMD: 🆕@CD_AACR Functional STK11 mutations is associated with resistance to ICIs in #lungcancer & is reversed by STAT3 knockdown…
RT @APassaroMD: 🆕@CD_AACR Functional STK11 mutations is associated with resistance to ICIs in #lungcancer & is reversed by STAT3 knockdown…
🆕@CD_AACR Functional STK11 mutations is associated with resistance to ICIs in #lungcancer & is reversed by STAT3 knockdown 🌟 #LCSM https://t.co/vKnWE5toDW https://t.co/QujMf4ViRl
From the Nov. issue: Resistance to durvalumab and durvalumab plus tremelimumab is associated with functional #STK11 mutations in non-small-cell #lungcancer patients and is reversed by STAT3 knockdown. https://t.co/tVWXlYsK7X @nabendu71 @MLAscierto et. al
RT @cancer_evolve: LUNG: somatic mutation of STK11, a known marker of resistance to checkpoint inhibition, has been associated with an immu…
RT @cancer_evolve: LUNG: somatic mutation of STK11, a known marker of resistance to checkpoint inhibition, has been associated with an immu…
LUNG: somatic mutation of STK11, a known marker of resistance to checkpoint inhibition, has been associated with an immunosuppressive microenvironment driven by STAT3-dependent myeloid cells, highlighting STAT3 as a potential therapeutic target. https://t.
RT @giusvisc: Resistance to durvalumab +- tremelimumab in STK11 mutant NSCLC driven by changes in TME and peripheral immunophenotype. Modul…
RT @giusvisc: Resistance to durvalumab +- tremelimumab in STK11 mutant NSCLC driven by changes in TME and peripheral immunophenotype. Modul…
RT @giusvisc: Resistance to durvalumab +- tremelimumab in STK11 mutant NSCLC driven by changes in TME and peripheral immunophenotype. Modul…
RT @giusvisc: Resistance to durvalumab +- tremelimumab in STK11 mutant NSCLC driven by changes in TME and peripheral immunophenotype. Modul…
RT @giusvisc: Resistance to durvalumab +- tremelimumab in STK11 mutant NSCLC driven by changes in TME and peripheral immunophenotype. Modul…
RT @giusvisc: Resistance to durvalumab +- tremelimumab in STK11 mutant NSCLC driven by changes in TME and peripheral immunophenotype. Modul…
Resistance to durvalumab +- tremelimumab in STK11 mutant NSCLC driven by changes in TME and peripheral immunophenotype. Modulation of STAT3 could reverse resistance? #lungcancer https://t.co/jV3510wCPj
RT @PazAresLab: Resistance to Durvalumab and Durvalumab plus Tremelimumab Is Associated with Functional STK11 Mutations in Patients with No…
RT @PazAresLab: Resistance to Durvalumab and Durvalumab plus Tremelimumab Is Associated with Functional STK11 Mutations in Patients with No…
Resistance to Durvalumab and Durvalumab plus Tremelimumab Is Associated with Functional STK11 Mutations in Patients with Non–Small Cell Lung Cancer and Is Reversed by STAT3 Knockdown https://t.co/kbgr9BgTN8
RT @ElizSMcKenna: Now online in @CD_AACR: Resistance to durvalumab and durvalumab plus tremelimumab is associated with functional #STK11 mu…
RT @chfloudas: MT @CD_AACR: Resistance to durvalumab and durva plus treme is associated with functional #STK11 mutations in NSCLC patients…
Resistance to durvalumab and durvalumab plus tremelimumab is associated with functional STK11 mutations in non-small-cell lung cancer patients and is reversed by STAT3 knockdown | Cancer Discovery https://t.co/nQzckX6SXz
RT @chfloudas: MT @CD_AACR: Resistance to durvalumab and durva plus treme is associated with functional #STK11 mutations in NSCLC patients…
RT @chfloudas: MT @CD_AACR: Resistance to durvalumab and durva plus treme is associated with functional #STK11 mutations in NSCLC patients…
MT @CD_AACR: Resistance to durvalumab and durva plus treme is associated with functional #STK11 mutations in NSCLC patients and is reversed by STAT3 knockdown, by @nabendu71 @MLAscierto et al. https://t.co/xHbSq7ZGlx #immunotherapy https://t.co/QOH5YtCkvU
RT @ElizSMcKenna: Now online in @CD_AACR: Resistance to durvalumab and durvalumab plus tremelimumab is associated with functional #STK11 mu…
RT @ElizSMcKenna: Now online in @CD_AACR: Resistance to durvalumab and durvalumab plus tremelimumab is associated with functional #STK11 mu…
Resistance to durvalumab and durvalumab plus tremelimumab is associated with functional #STK11 mutations in non-small-cell #lungcancer patients and is reversed by STAT3 knockdown, by @nabendu71 @MLAscierto and colleagues. https://t.co/w5XWHhzEXi #immunothe
RT @ElizSMcKenna: Now online in @CD_AACR: Resistance to durvalumab and durvalumab plus tremelimumab is associated with functional #STK11 mu…
RT @ElizSMcKenna: Now online in @CD_AACR: Resistance to durvalumab and durvalumab plus tremelimumab is associated with functional #STK11 mu…
RT @ElizSMcKenna: Now online in @CD_AACR: Resistance to durvalumab and durvalumab plus tremelimumab is associated with functional #STK11 mu…
RT @ElizSMcKenna: Now online in @CD_AACR: Resistance to durvalumab and durvalumab plus tremelimumab is associated with functional #STK11 mu…
RT @ElizSMcKenna: Now online in @CD_AACR: Resistance to durvalumab and durvalumab plus tremelimumab is associated with functional #STK11 mu…
RT @ElizSMcKenna: Now online in @CD_AACR: Resistance to durvalumab and durvalumab plus tremelimumab is associated with functional #STK11 mu…
RT @ElizSMcKenna: Now online in @CD_AACR: Resistance to durvalumab and durvalumab plus tremelimumab is associated with functional #STK11 mu…
RT @ElizSMcKenna: Now online in @CD_AACR: Resistance to durvalumab and durvalumab plus tremelimumab is associated with functional #STK11 mu…
RT @ElizSMcKenna: Now online in @CD_AACR: Resistance to durvalumab and durvalumab plus tremelimumab is associated with functional #STK11 mu…
RT @ChristianRolfo: @isliquidbiopsy @OncoAlert
@isliquidbiopsy @OncoAlert
RT @ElizSMcKenna: Now online in @CD_AACR: Resistance to durvalumab and durvalumab plus tremelimumab is associated with functional #STK11 mu…
RT @ElizSMcKenna: Now online in @CD_AACR: Resistance to durvalumab and durvalumab plus tremelimumab is associated with functional #STK11 mu…
Now online in @CD_AACR: Resistance to durvalumab and durvalumab plus tremelimumab is associated with functional #STK11 mutations in NSCLC and is reversed by #STAT3 knockdown, by @nabendu71 @MLAscierto and colleagues @AstraZeneca #immunotherapy https://t.co
Resistance to durvalumab and durvalumab plus tremelimumab is associated with functional STK11 mutations in non-small-cell lung cancer patients and is reversed by STAT3 knockdown https://t.co/uAUzTw0Ciz https://t.co/oWbMTzFaGU